Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 1Kidney Neoplasms 1Kidney Failure, Chronic 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 21cabozantinib 12Specimen Handling 11Ipilimumab 10belzutifan 9pembrolizumab 8Magnetic Resonance Spectroscopy 8CTLA-4 Antigen 5Biopsy 5Axitinib 5lenvatinib 4Sunitinib 4Immunoglobulin G 3Disulfides 3zimberelimab 2tivozanib 2relatlimab 2pazopanib 2palbociclib 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2Radiosurgery 2Nephrectomy 2Bevacizumab 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × orellanine × 30 days × Clear all
NCT05287945 2026-05-22

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Oncorena AB

Phase 1/2 Recruiting
75 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡